- Home
- CCS vs IBRX Comparison
CCS vs IBRX Comparison
Compare CCS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCS
- IBRX
- Stock Information
- Founded
- CCS 2000
- IBRX 2014
- Country
- CCS United States
- IBRX United States
- Employees
- CCS N/A
- IBRX N/A
- Industry
- CCS Homebuilding
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCS Consumer Discretionary
- IBRX Health Care
- Exchange
- CCS Nasdaq
- IBRX Nasdaq
- Market Cap
- CCS 2.7B
- IBRX 2.4B
- IPO Year
- CCS 2014
- IBRX N/A
- Fundamental
- Price
- CCS $62.92
- IBRX $2.97
- Analyst Decision
- CCS Buy
- IBRX Strong Buy
- Analyst Count
- CCS 4
- IBRX 5
- Target Price
- CCS $104.00
- IBRX $11.35
- AVG Volume (30 Days)
- CCS 512.2K
- IBRX 5.7M
- Earning Date
- CCS 04-23-2025
- IBRX 03-03-2025
- Dividend Yield
- CCS 1.84%
- IBRX N/A
- EPS Growth
- CCS 29.19
- IBRX N/A
- EPS
- CCS 10.40
- IBRX N/A
- Revenue
- CCS $4,398,288,000.00
- IBRX $14,745,000.00
- Revenue This Year
- CCS $11.95
- IBRX $621.53
- Revenue Next Year
- CCS $7.41
- IBRX $163.57
- P/E Ratio
- CCS $6.05
- IBRX N/A
- Revenue Growth
- CCS 19.12
- IBRX 2270.58
- 52 Week Low
- CCS $62.29
- IBRX $2.28
- 52 Week High
- CCS $108.42
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- CCS 31.00
- IBRX 49.44
- Support Level
- CCS $65.22
- IBRX $2.90
- Resistance Level
- CCS $68.25
- IBRX $3.26
- Average True Range (ATR)
- CCS 2.27
- IBRX 0.22
- MACD
- CCS -0.32
- IBRX 0.03
- Stochastic Oscillator
- CCS 6.58
- IBRX 36.71
About CCS Century Communities Inc.
Century Communities Inc is a construction company that focuses on the residential market. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its own sales representatives and independent real estate brokers. It also advertises directly to potential homebuyers through the Internet, newspapers, and trade publications. The company generates the majority revenue from the Mountain segment.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.